|3.||Graft vs Host Disease (Graft-Versus-Host Disease)
|1.||Chen, Huan: 13 articles (12/2013 - 08/2004)|
|2.||Huang, Xiao-jun: 12 articles (12/2013 - 08/2004)|
|3.||Liu, Dai-hong: 10 articles (12/2013 - 08/2004)|
|4.||Huang, Xiao-Jun: 9 articles (01/2014 - 08/2008)|
|5.||Xu, Lan-ping: 9 articles (12/2013 - 08/2004)|
|6.||Han, Wei: 9 articles (03/2013 - 08/2004)|
|7.||Liu, Kai-yan: 8 articles (12/2013 - 08/2004)|
|8.||Taniguchi, Shuichi: 8 articles (05/2008 - 06/2004)|
|9.||Liu, Hong: 7 articles (09/2014 - 03/2002)|
|10.||Miyakoshi, Shigesaburo: 7 articles (05/2008 - 06/2004)|
|1.||rituximab (Mabthera)FDA Link
02/01/2014 - "The remission of NS in our patient with rituximab seems to emphasize the pathogenetic role of B cells in MCD, although a coincident effect of immunosuppression on both the underlying renal disease and the hematologic disease cannot be excluded."
01/01/2014 - "Rituximab, a chimeric anti-CD20 monoclonal antibody, is used to treat rheumatologic and hematologic diseases. "
08/01/2011 - "Rituximab, an anti-CD20 antibody, was the first monoclonal antibody successfully developed for treatment of malignant hematologic diseases. "
01/01/2011 - "The monoclonal antibody anti- CD20 rituximab represents the best example of these advances and has quickly become incorporated into the therapeutic armamentarium for this hematological disease. "
04/01/2010 - "Rituximab in autoimmune hematologic diseases: not just a matter of B cells."
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)IBA
10/10/2002 - "An effective treatment for malignant hematological disease, G-CSF mobilized allogeneic bone marrow plus peripheral blood stem cells transplantation provides rapid and sustained engraftment without increase in incidence of aGVHD and cGVHD."
10/10/2002 - "To study the feasibility and clinical outcome of granulocyte-colony stimulating factor (G-CSF) mobilized allogeneic bone marrow (G-BM) plus G-CSF mobilized peripheral blood stem cells (G-PBSC) transplantation for malignant hematological disease. "
10/10/2002 - "[A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases]."
09/01/2014 - "On the contrary, there might be space for their use, mainly for G-CSF, in case of severe infectious complications in severely neutropenic neonates (absolute polymorphonuclear neutrophil count <500/μL) and/or in the presence of specific hematological diseases causing neutropenia."
08/01/2014 - "Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases."
|3.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/01/2001 - "Retrospective case series have also shown that pulse cyclophosphamide therapy may be effective for the management of severe or refractory to standard therapy neuropsychiatric, pulmonary, cardiovascular and hematologic disease. "
05/01/2002 - "The aim of this study was to estimate noninvasively the cardiotoxicity of cyclophosphamide administered during the pretransplant conditioning of BSCT for patients with various hematological diseases. "
03/21/1965 - "[APROPOS OF THE USE OF CYCLOPHOSPHAMIDE IN 28 CASES OF MALIGNANT BLOOD DISEASES]."
01/01/2015 - "Cyclophosphamide is commonly used as an important component in conditioning prior to hematopoietic stem cell transplantation, a curative treatment for several hematological diseases. "
10/01/2008 - "Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases."
|4.||Itraconazole (Sporanox)FDA LinkGeneric
12/01/2008 - "Sequential intravenous and oral itraconazole therapy was effective for IFI and tolerated well in patients with hematological diseases."
12/01/2008 - "Itraconazole is an effective and safe antifungal agent for patients with hematological disease or undergoing HSCT and is suitable for empirical antifungal therapy."
06/08/2005 - "Fungal infections in immunocompromised patients with hematological diseases can be successfully treated with intravenous administration of itraconazole."
06/08/2005 - "To investigate the efficacy of intravenous administration of itraconazole on fungal infections in immunocompromised patients with hematological diseases according to stratified diagnoses. "
06/08/2005 - "[Efficacy of intravenous administration of itraconazole on fungal infections in immunocompromised patients with hematological diseases]."
|5.||Miconazole (Monistat)FDA LinkGeneric
08/01/1992 - "[Plasma beta-glucan levels in deep fungal infections accompanying hematological diseases and clinical efficacy of miconazole--a multi-institutional study]."
06/01/1994 - "[Clinical studies of a newly developed miconazole preparation for intravenous drip infusion (MJR-1761) in hematologic disease patients with deep-seated fungal infections]."
06/01/1994 - "The efficacy and safety of a newly developed miconazole preparation (MJR-1761) for intravenous drip infusion were evaluated in 22 patients with hematological diseases complicated by documented or suspected deep-seated fungal infections. "
06/01/1995 - "[Efficacy of combination chemotherapy with miconazole and G-CSF in deep mycosis accompanying hematological diseases]."
|6.||Thalidomide (Thalomid)FDA Link
01/01/2010 - "[Thalidomide in oncological and hematological diseases]."
03/01/2002 - "[Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy]."
02/01/2005 - "Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases. "
10/01/2004 - "Thalidomide is an anti-angiogenic drug that has shown promise in multiple hematological diseases, and myeloma and other cancers. "
09/01/2006 - "Herein the incidence of thalidomide-associated bradycardia in patients with hematologic diseases treated in a single institution is reported. "
|7.||Doxorubicin (Adriamycin)FDA LinkGeneric
12/01/2002 - "Adriamycin is a potent, broad-spectrum chemotherapeutic agent effective against solid tumors and malignant hematological disease. "
09/01/2013 - "The cardiotoxicity of doxorubicin limits its clinical use in the treatment of a variety of solid tumors and malignant hematologic disease. "
01/01/2010 - "The cardiotoxicity of doxorubicin limits its clinical use in the treatment of a variety of solid tumors and malignant hematologic disease. "
02/01/2005 - "The cardiotoxicity of adriamycin limits its clinical use as a powerful drug for solid tumors and malignant hematological disease. "
09/01/2013 - "The two men reactivated after eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone and the one woman after 13 cycles of rituximab monotherapy; their hematologic disease was in remission. "
12/01/2013 - "This study was aimed to distinguish abnormal cells and to diagnose hematologic diseases through recognizing antigen expression pattern and percentage of peripheral blood cells in normal elderly men. "
02/01/2012 - "Although interstudy heterogeneity existed, most studies were conducted in the United States or Europe and included adult patients with hematologic disease who received alloHSCT from human leukocyte antigen-matched or identical sibling donors. "
04/01/2010 - "The aim of this study was to explore the feasibility and safety of cotransplantation culture-expanded MSCs and HSCs from the same human leukocyte antigen (HLA)-identical sibling donor in Chinese patients with hematologic diseases. "
03/01/2006 - "The purpose of this study was to double label canine blood for CD18 and CD45 and to use the differential expression of antigens to identify leukocyte populations in dogs with non-neoplastic and neoplastic hematologic diseases. "
06/01/2013 - "[HLA antigen compatibility between patients with hematologic diseases and their parents]."
|9.||Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/01/1994 - "Over the past decade, Hematopoietic Growth Factors (HGFs) have been shown to improve the treatment of malignant blood diseases. "
02/01/1990 - "The availability of recombinant growth factors has stimulated clinical trials of these factors in a wide variety of hematologic diseases."
11/01/2006 - "Modelling hematopoiesis mediated by growth factors with applications to periodic hematological diseases."
07/01/2001 - "In pediatric patients with hematological diseases, there are only few data on the use of hematopoietic growth factors in children with myelodysplastic syndrome. "
06/01/2015 - "Secondary CLSs are mostly due to malignant hematological diseases, viral infections, and treatments such as chemotherapies and therapeutic growth factors. "
|10.||Complement System Proteins (Complement)IBA
10/04/1959 - "[Study of the level of total complement in the course of various blood diseases]."
05/01/2000 - "[Fluorescent in situ hybridization (FISH), cytogenetic analytical complement for the diagnosis of malignant blood diseases]."
01/01/1977 - "Role of complement in the pathophysiology of hematologic diseases."
07/06/1964 - "[BEHAVIOR OF SERUM COMPLEMENT IN SOME BLOOD DISEASES]."
01/01/1958 - "[Complement content of human sera in autoimmunological-caused blood diseases]."
06/01/2013 - "Laparoscopic splenectomy (LS) is nowadays considered as the gold standard for most hematological diseases where splenectomy is necessary, but many questions still remain. "
07/01/1999 - "With careful perioperative management, splenectomy is both safe and beneficial in a selected group of patients with hematological diseases."
01/01/2015 - "Indications of splenectomy for hematologic diseases have been reducing in the last few years, due to improved diagnostic and therapeutic tools. "
02/01/1997 - "Laparoscopic splenectomy is a safe and effective alternative to open splenectomy for treatment of hematologic diseases in patients of all ages."
11/01/1996 - "Laparoscopic splenectomy by the lateral approach: a safe and effective alternative to open splenectomy for hematologic diseases."
|2.||Transplantation (Transplant Recipients)
09/01/2000 - "Understanding the many aspects of the switch from embryonic to fetal to adult erythropoiesis can lead to an improved awareness of many of the problems typical of preterm infants, inborn errors resulting in hematologic diseases, and aspects important for transplantation medicine."
01/01/2013 - "Nowadays, HSC transplantation and hematopoietic cell transfusion have successfully cured some patients, especially in malignant hematological diseases. "
07/01/1999 - "Transplantation of hematopoietic stem cells (HSC) is an effective treatment for a number of patients with life-threatening hematologic diseases. "
06/01/1985 - "Marrow transplantation is effective treatment for a number of hematological diseases in patients under the age of 50 who have an HLA-identical sibling donor. "
01/01/2003 - "In utero transplantation of hematopoietic stem cells is a promising treatment for immune and hematologic diseases of fetuses and newborns. "
|3.||Hematopoietic Stem Cell Transplantation
01/01/2011 - "Allogeneic hematopoietic stem cell transplantation (AHSCT) offers the best chance of cure for many patients with congenital and acquired hematologic diseases. "
10/01/2013 - "This study was aimed to investigate the efficacy of haploidentical hematopoietic stem cell transplantation (hi-HSCT) combined with umbilical cord mesenchymal stem cells (MSC) using modified conditioning regimen for the treatment of patients with refractory and relapsed or high risk malignant hematologic diseases, the clinical efficacy in 30 patients with refractory and relapsed or high risk malignant, who voluntarily received HSCT was analyzed. "
04/01/2014 - "[Therapeutic efficacy of mixed hematopoietic stem cell transplantation for pediatric hematologic diseases]."
01/01/2014 - "Hematopoietic stem cell transplantation (HSCT) is a definite cure for many hematological diseases. "
12/01/2013 - "Umbilical cord blood is an alternative hematopoietic stem cell source for treatment of hematological diseases that can be cured by allogeneic hematopoietic stem cell transplantation. "
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
01/01/1994 - "Recent progress in bone marrow transplantation (BMT) has dramatically improved the prognosis of otherwise fatal hematological diseases. "
01/01/1987 - "Since the 1970s major progress in bone marrow transplantation has resulted in long-term survival and even cure for many patients with serious hematologic disease. "
11/01/1962 - "[On the therapeutic efficacy of bone marrow transplantation in some blood diseases]."
10/01/2000 - "A total of 108 consecutive patients treated with allogeneic bone marrow transplantation from an HLA-identical sibling donor for malignant blood disease were entered into the study; 53 patients were randomized to receive and 55 were randomized not to receive prophylactic MP. "
02/01/1999 - "The present study included 26 patients with hematological diseases who had undergone allogeneic bone marrow transplantation (BMT). "
10/01/2003 - "The aim of this study was to determine whether nonmyeloablative transplants (NMT) result in complete and sustained donor engraftment in patients with progressive hematologic diseases compared to patients with stable disease or who are in remission. "
09/01/2005 - "Sixteen patients (50%) had a relapsed or resistant hematologic disease, while 12 patients were in complete remission and 4 were at onset of disease; 8/32 (25%) developed IFI after a hematopoietic stem cell transplant (HSCT) procedure. "
06/01/2015 - "The results of the current study suggest that for patients with high-risk hematological diseases without a related or unrelated donor, haploidentical transplants are a promising alternative option that deserves further investigation."
06/01/2015 - "In the present study 126 patients were identified suffering from hematological diseases requiring MUD transplant. "
06/01/2015 - "The study was conducted at National Institute of Blood Disease and Bone Marrow Transplant. "